[{"id":"systimmune","kind":"company","name":"SystImmune / Sichuan Biokin","route":"/companies/systimmune/","commit":"067761977c","date":"2026-09-10","author":"Jude Gomila","message":"Sources: official-website links on every remaining company","file":"src/data/companies.ts","type":"changed","fields":[{"field":"links","after":"[{ label: \"Official website\", url: \"https://www.systimmune.com\" }]"}]},{"id":"systimmune","kind":"company","name":"SystImmune / Sichuan Biokin","route":"/companies/systimmune/","commit":"01c3b96cd7","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch D: Builders and investors","file":"src/data/sponsor-aliases.ts","type":"added","fields":[{"field":"id"},{"field":"label"},{"field":"kind"}]},{"id":"systimmune","kind":"company","name":"SystImmune / Sichuan Biokin","route":"/companies/systimmune/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/companies.ts","type":"changed","fields":[{"field":"tldr","before":"\"Developer of iza-bren, the first bispecific ADC to win a phase 3 trial.\"","after":"\"SystImmune developed iza-bren, the first bispecific ADC to win a phase 3 trial.\""}]}]